The efficacy of sapacitabine in treating patients with acute myeloid leukemia. (2nd November 2018)

• Record Type: Journal Article
• Authors: Czemerska, Magdalena; Robak, Tadeusz; Wierzbowska, Agnieszka
• Is Part Of: Expert opinion on pharmacotherapy. Volume 19:Number 16(2018)
• Page Start: 1835
• Page End: 1839
• Publication Date: 2018-11-02
• Subjects: Sapacitabine -- acute myeloid leukemia -- chemotherapy -- elderly; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2018.1524875
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Acute myeloid leukemia (AML) remains a poor prognosis hematological malignancy. The introduction of aggressive chemotherapy with allogeneic stem cell transplantation has resulted in improved clinical outcomes in younger patients. However, the treatment results in unfit elderly AML population remain disappointing. New strategies should be introduced to improve the prognosis in this group of patients. Areas covered : This review presents and discusses the mechanism of action, safety and efficacy of sapacitabine in AML patients. Expert opinion : Sapacitabine, a novel nucleoside analog, seemed to be a promising new agent for AML treatment. Its oral bioavailability and tolerable toxicity profile allow the drug to be used in an outpatient setting, especially in elderly unfit patients. Sapacitabine is known to have antileukemic activity in randomized clinical trials. In AML patients, sapacitabine monotherapy offered no advantage over low-intensity cytarabine treatment, and the combination of sapacitabine with decitabine was not significantly more effective than decitabine alone. However, the oral administration of sapacitabine allows it to be used in AML maintenance therapy.